Fig. 12From: Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptidesa Afatinib- and/or miR139-loaded LPN-HR inhibited EGFR/HR signaling via suppression of Ras-, Akt-, Rac1-, and STAT3-mediated pathways. b Schematic diagram of peptide H- and peptide R-modified lipid polymeric nanoparticles incorporating afatinib and miR-139 to intensify anticancer activity against CRC cellsBack to article page